Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $70.55 | Total: $352.75 |
| 1 | 10 | $59.76 | Total: $597.60 |
| 1 | 25 | $50.63 | Total: $1,265.75 |
| 1 | 50 | $43.16 | Total: $2,158.00 |
| 1 | 100 | $37.35 | Total: $3,735.00 |
Overview
Bemnifosbuvir (AT-511), a novel phosphoramidate prodrug of 2'-fluoro-2'-C-methylguanosine-5'-monophosphate, exhibits potent in vitro activity against HCV.
Chemical Properties
| Molecular Formula | C24H33FN7O7P |
| Molecular Weight | 581.53 |
| CAS Numbers | 1998705-64-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C[C@]1(F)[C@H](N2C=3C(N=C2)=C(NC)N=C(N)N3)O[C@H](COP(OC4=CC=CC=C4)(N[C@H](C(OC(C)C)=O)C)=O)[C@H]1O |
Storage and Handling
0C Short Term, -20C Long Term
References
Steven S Good, et al. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS One. 2020 Jan 8;15[1] e0227104.